Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;16(8):1215-1219.
doi: 10.25122/jml-2023-0057.

Common clinical laboratory features among women with polycystic ovary syndrome and metabolic syndrome

Volodymyr Artyomenko  1 , Valentyna Velychko  2 , Daria Lahoda  2 , Halyna Danylchuk  2
Affiliations

Common clinical laboratory features among women with polycystic ovary syndrome and metabolic syndrome

Volodymyr Artyomenko et al. J Med Life. 2023 Aug.

Abstract

Women with polycystic ovary syndrome (PCOS) have a high prevalence of metabolic syndrome (MS), with rates up to 33%. This is associated with long-term consequences such as cardiovascular diseases, type 2 diabetes mellitus (T2DM), cancer, sleep apnea, and psychological issues. The prevalence of MS worldwide is often associated with obesity and T2DM, yet regional variations are reported. In this study, 122 women consulting general practice and family medicine physicians were evaluated, revealing a BMI exceeding 30 kg/m2. Among MS criteria, the most common diagnoses were T2DM in 29 patients, insulin resistance (IR) in 36, arterial hypertension (AH) in 51, reduced HDL levels in 53, and elevated triglycerides in 39. Further analysis revealed 16 unique combinations of MS components in these patients, with 75% of PCOS cases exhibiting three MS components and 25% having four. Additionally, research indicated that most women with PCOS face persistent, treatment-resistant obesity, with a notably higher BMI (ρ=0.87; r=0.76). These findings highlight the multifactorial nature of PCOS and MS etiology.

Keywords: comorbid pathology; insulin resistance; lipids; metabolic syndrome; obesity; polycystic ovary syndrome; pre-diabetes; triglycerides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The occurrence of polycystic ovary syndrome in relation to metabolic syndrome
Figure 2
Figure 2
Prevalence of various metabolic syndrome components among participants
See this image and copyright information in PMC

References

    1. Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, et al. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study. Front Endocrinol. 2022;13:825528. doi: 10.3389/fendo.2022.825528. - DOI - PMC - PubMed
    1. Artyomenko VV, Chumak ZV, Shapoval MV. The retrospective analysis results of the endometrial tissue pathological conditions development. Reprod Endocrinol. 2020;55:48–52. doi: 10.18370/2309-4117.2020.55.48-52. - DOI
    1. Hirode G, Wong RJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020;323(24):2526–2528. doi: 10.1001/jama.2020.4501. - DOI - PMC - PubMed
    1. Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451–63. - PubMed
    1. Artyomenko VV, Velychko VI, Lahoda DO. New approaches to early detection of polycystic ovary syndrome in obese women. Reprod Endocrinol. 2022;62:20–25.

MeSH terms

LinkOut - more resources